Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma

NCT00003958 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00003958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
Not reported
Enrollment
702 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult malignant mesenchymoma, adult rhabdomyosarcoma, alveolar childhood rhabdomyosarcoma, childhood malignant mesenchymoma, embryonal childhood rhabdomyosarcoma, embryonal-botryoid childhood rhabdomyosarcoma, nonmetastatic childhood soft tissue sarcoma, previously untreated childhood rhabdomyosarcoma, stage i adult soft tissue sarcoma, stage ii adult soft tissue sarcoma, stage iii adult soft tissue sarcoma